Le Lézard
Classified in: Health

Invitae Reports Inducement Grants Under NYSE Rule 303A.08

SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted restricted stock units ("RSUs") to Kenneth D. Knight, Invitae's new Chief Operating Officer and Karthik Suri, Invitae's new Chief Digital Officer. The RSUs were granted under Invitae's 2015 Stock Incentive Plan, which was amended and restated to create an additional pool of 475,000 shares of Invitae common stock to be used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ("Rule 303A.08"). The RSUs were approved by the Board of Directors of Invitae and were made as an inducement material to each employee entering into employment with Invitae in reliance on the employment inducement exemption under Rule 303A.08.

In connection with his appointment as Chief Operating Officer, Mr. Knight was granted an inducement award of 250,000 RSUs, with one-third of the RSUs vesting on each of the first three anniversaries of May 15, 2020, subject to his continued service as an employee of Invitae through the applicable vesting dates. Mr. Knight was granted an additional 75,000 RSUs which will vest with respect to 50% of the common stock underlying the RSUs on December 15, 2020, and with respect to the remainder, on June 15, 2021.

Mr. Suri was granted an award of 150,000 RSUs in connection with his appointment as Chief Digital Officer, with one-third of the RSUs vesting on each of the first three anniversaries of May 15, 2020, subject to his continued service as an employee of Invitae through the applicable vesting dates.

All RSU grants described above will be subject to the terms and conditions of the 2015 Stock Incentive Plan and the applicable stock award agreements.

About Invitae
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.

Source: Invitae Corporation

Laura D'Angelo
(628) 213-3369

SOURCE Invitae Corporation

These press releases may also interest you

25 sep 2020
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Vaxart, Inc. . In early 2020, the Company, which focuses on...

25 sep 2020
Montage Resources Corporation WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Montage Resources Corporation in connection with the proposed acquisition of the company by...

25 sep 2020
The National Society of College Scholars (NSCS) is proud to announce a new community service partnership with The Alzheimer's Association. NSCS members will participate in a community service project through The Alzheimer's Association's Longest Day®...

25 sep 2020
Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceuticals, Inc.  ("BioMarin" or the "Company") and certain of its officers.   The class action, filed in United States District Court for the Northern District...

25 sep 2020
Century Specialty Script, LLC ("Century"), a specialty pharmacy which provides an array of specific and personalized services in all pharmacy related matters, announced today that it has taken action after learning of a data security incident which...

25 sep 2020
ILJIN SNT Co., Ltd. ("ILJIN SNT") announces that, based on information contained in documents filed publicly by Aurinia Pharmaceuticals Inc. ("Aurinia"), ILJIN SNT has ceased to be an insider of Aurinia. On July 27, 2020, Aurinia completed an...

News published on 4 august 2020 at 18:37 and distributed by: